Stryker (SYK) Sees Higher Price Target from UBS amid Continued MedTech Strength

Stryker Corporation (NYSE:SYK) is included among the 13 Best Performing Long Term Stocks to Invest in.

On February 24, UBS raised its price recommendation on Stryker Corporation (NYSE:SYK) to $400 from $386. The firm kept a Neutral rating on the stock.

During the Q4 2025 earnings call, CEO Kevin Lobo described 2025 as an outstanding year. He said both the fourth quarter and the full year delivered strong results across key financial measures. Organic sales increased 11% in the fourth quarter and 10.3% for the full year. This helped push total revenue past $25 billion. He noted that growth came from multiple parts of the business. Neurocranial, Endoscopy, Instruments, and Trauma and Extremities all delivered double-digit organic sales growth worldwide. This showed that performance was not limited to one area but spread across the portfolio. He added that “Full-year U.S. organic sales growth was an impressive 11.2%, and international organic sales growth of 7.5%,” and indicated that emerging markets, along with South Korea and Japan, contributed meaningfully to international growth.

Lobo also spoke about steps taken to strengthen the company’s long-term position. He said the company created the SmartCare business unit by combining Vocera and care.ai. This move brought its digital healthcare solutions under one structure. He also pointed to the launch of a dedicated breast care sales team within the Endoscopy segment, which was intended to increase focus and improve execution in that area.

Stryker Corporation (NYSE:SYK) is a medical technology company. It provides products and services across MedSurg, Neurotechnology, and Orthopaedics to support better patient and healthcare outcomes. Its business is organized into two main segments: MedSurg and Neurotechnology, and Orthopaedics.

While we acknowledge the potential of SYK as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: 14 Value Stocks to Buy With High Dividend Yields and 13 Best March Dividend Stocks to Buy

Disclosure: None.  Follow Insider Monkey on Google News.